HRP20180204T1 - Spojevi tioninija i njihova primjena - Google Patents
Spojevi tioninija i njihova primjena Download PDFInfo
- Publication number
- HRP20180204T1 HRP20180204T1 HRP20180204TT HRP20180204T HRP20180204T1 HR P20180204 T1 HRP20180204 T1 HR P20180204T1 HR P20180204T T HRP20180204T T HR P20180204TT HR P20180204 T HRP20180204 T HR P20180204T HR P20180204 T1 HRP20180204 T1 HR P20180204T1
- Authority
- HR
- Croatia
- Prior art keywords
- thioninium
- ethyl
- iodide
- chloride
- mixture
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 4
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 10
- 238000011282 treatment Methods 0.000 claims 9
- -1 diaminophenothiazinium compound Chemical class 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 8
- DNECCZDSSLSZQV-UHFFFAOYSA-N 2-methylthionin-1-ium;iodide Chemical compound [I-].CC1=CC=CC=CC=C[SH+]1 DNECCZDSSLSZQV-UHFFFAOYSA-N 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 238000011321 prophylaxis Methods 0.000 claims 5
- TYPZVZGDFLZJJI-UHFFFAOYSA-N 2-ethylthionin-1-ium;iodide;hydroiodide Chemical class I.[I-].CCC1=CC=CC=CC=C[SH+]1 TYPZVZGDFLZJJI-UHFFFAOYSA-N 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 4
- FPYZHSXBQLJMRL-UHFFFAOYSA-O [O-][N+]([O-])=O.CCC1=CC=CC=CC=C[SH+]1 Chemical compound [O-][N+]([O-])=O.CCC1=CC=CC=CC=C[SH+]1 FPYZHSXBQLJMRL-UHFFFAOYSA-O 0.000 claims 4
- 239000012752 auxiliary agent Substances 0.000 claims 4
- 230000007850 degeneration Effects 0.000 claims 4
- 239000003085 diluting agent Substances 0.000 claims 4
- 238000011156 evaluation Methods 0.000 claims 4
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 4
- MFNXMMSWKMRQAC-UHFFFAOYSA-N 2-methylthionin-1-ium;iodide;hydroiodide Chemical compound I.[I-].CC1=CC=CC=CC=C[SH+]1 MFNXMMSWKMRQAC-UHFFFAOYSA-N 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 102000013498 tau Proteins Human genes 0.000 claims 3
- 108010026424 tau Proteins Proteins 0.000 claims 3
- QEDUHXBYRDKOHF-UHFFFAOYSA-N 2-butan-2-yl-9-ethylthionin-1-ium chloride Chemical compound [Cl-].C(C)C(C)C=1[SH+]C(=CC=CC=CC1)CC QEDUHXBYRDKOHF-UHFFFAOYSA-N 0.000 claims 2
- OHDAQDDEICWOEH-UHFFFAOYSA-N 2-ethylthionin-1-ium;iodide Chemical compound [I-].CCC1=CC=CC=CC=C[SH+]1 OHDAQDDEICWOEH-UHFFFAOYSA-N 0.000 claims 2
- 206010002027 Amyotrophy Diseases 0.000 claims 2
- 206010012289 Dementia Diseases 0.000 claims 2
- 208000027089 Parkinsonian disease Diseases 0.000 claims 2
- 206010034010 Parkinsonism Diseases 0.000 claims 2
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 2
- 208000034799 Tauopathies Diseases 0.000 claims 2
- RZDRZZNQWOLYQR-UHFFFAOYSA-M [Cl-].C(C)[S+]1C(=CC=CC=CC=C1CC)C Chemical compound [Cl-].C(C)[S+]1C(=CC=CC=CC=C1CC)C RZDRZZNQWOLYQR-UHFFFAOYSA-M 0.000 claims 2
- PRZPHPNBPWCCJI-UHFFFAOYSA-N [Cl-].CC(C)C=1[SH+]C(=CC=CC=CC1)C Chemical compound [Cl-].CC(C)C=1[SH+]C(=CC=CC=CC1)C PRZPHPNBPWCCJI-UHFFFAOYSA-N 0.000 claims 2
- QFHKZASDZUVDPT-UHFFFAOYSA-N [Cl-].CCC1=CC=CC=CC=C[SH+]1 Chemical compound [Cl-].CCC1=CC=CC=CC=C[SH+]1 QFHKZASDZUVDPT-UHFFFAOYSA-N 0.000 claims 2
- LPVGCWANPNJFMY-UHFFFAOYSA-M [Cl-].[Cl-].[Zn+].CCC1=CC=CC=CC=C[SH+]1 Chemical compound [Cl-].[Cl-].[Zn+].CCC1=CC=CC=CC=C[SH+]1 LPVGCWANPNJFMY-UHFFFAOYSA-M 0.000 claims 2
- 210000000349 chromosome Anatomy 0.000 claims 2
- 230000003920 cognitive function Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229940126601 medicinal product Drugs 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010013142 Disinhibition Diseases 0.000 claims 1
- 239000004097 EU approved flavor enhancer Substances 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000975 dye Substances 0.000 claims 1
- 239000000945 filler Substances 0.000 claims 1
- 235000019264 food flavour enhancer Nutrition 0.000 claims 1
- 235000003599 food sweetener Nutrition 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 230000000873 masking effect Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 238000004393 prognosis Methods 0.000 claims 1
- 239000011833 salt mixture Substances 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 239000003381 stabilizer Substances 0.000 claims 1
- 239000004094 surface-active agent Substances 0.000 claims 1
- 239000003765 sweetening agent Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Claims (14)
1. Spoj diaminofenotiazinija, naznačen time, da je odabran od sljedećih:
(H) mješavina soli metil-tioninijev jodid-vodikov jodid (MTI.HI),
(J) mješavina soli etil-tioninijev jodid-vodikov jodid (ETI.HI),
(L) etil-tioninijev nitrat (ETN).
2. Spoj diaminofenotiazinija, naznačen time, da je odabran od sljedećih:
(J) mješavina soli etil-tioninijev jodid-vodikov jodid (ETI.HI), i
(L) etil-tioninijev nitrat (ETN).
3. Farmaceutski sastav, naznačen time, da se upotrebljava u postupku liječenja ili profilakse ljudskog ili životinjskog pojedinca putem terapije, pri čemu taj farmaceutski sastav obuhvaća spoj diaminofenotiazinija koji je odabran od sljedećih:
(A) etil-tioninijev klorid (ETC),
(B) 1,9-dietil-metil-tioninijev klorid (DEMTC),
(C) 1,9-dimetil-etil-tioninijev klorid (DMETC),
(D) 1,9-dietil-etil-tioninijev klorid (DEETC),
(F) mješavina soli etil-tioninijev klorid-zinkov klorid (ETZ),
(G) metil-tioninijev jodid (MTI),
(H) mješavina soli metil-tioninijev jodid-vodikov jodid (MTI.HI),
(I) etil-tioninijev jodid (ETI),
(J) mješavina soli etil-tioninijev jodid-vodikov jodid (ETI.HI),
(L) etil-tioninijev nitrat (ETN),
i farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
4. Farmaceutski sastav za uporabu prema zahtjevu 3, naznačen time, da je pojedinac odabran za liječenje slijedom procjene pomoću kliničke evaluacije i/ili slijedom objektivne evaluacije kognitivne funkcije primjenom neuropatološki validiranih baterija testova.
5. Farmaceutski sastav prema zahtjevu 3 ili zahtjevu 4, naznačen time, da nadalje obuhvaća jedan ili više ostalih farmaceutski prihvatljivih sastojaka odabranih od sljedećih farmaceutski prihvatljivih sredstava: nosači, razrjeđivači, pomoćna sredstva, adjuvanti, punila, puferi, konzervansi, antioksidansi, maziva, stabilizatori, otapala, tenzidi, maskirna sredstva, bojila, pojačivači okusa i zaslađivači.
6. Farmaceutski sastav prema bilo kojem od zahtjeva 3 do 5, naznačen time, da farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo jest ili obuhvaća jedan/jednoga ili oba od glicerida i/ili koloidalnog silicijevog dioksida.
7. Dozna jedinica, naznačena time, da obuhvaća od 20 do 300 mg spoja diaminofenotiazinija prema zahtjevu 1 ili zahtjevu 2 te farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
8. Dozna jedinica prema zahtjevu 7, naznačena time, da je ona tableta ili kapsula.
9. Dozna jedinica prema zahtjevu 7, naznačena time, da je spoj diaminofenotiazinija prisutan u količini od 30 do 200 mg.
10. Ljekoviti proizvod, naznačen time, da služi za liječenje bolesnog stanja
povezanog s agregacijom tau proteina kod sisavca koji boluje od toga stanja, obuhvaćajući označeni spremnik ili spremnik udružen s oznakom koja pokazuje da taj ljekoviti proizvod služi za liječenje spomenute bolesti, pri čemu spremnik sadrži jednu ili više doznih jedinica od kojih svaka obuhvaća najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, te kao djelatni sastojak obuhvaća izolirani čisti spoj diaminofenotiazinija prema zahtjevu 1 ili zahtjevu 2.
11. Farmaceutski sastav prema bilo kojem od zahtjeva 3 do 6:
naznačen time, da se upotrebljava u postupku liječenja ili profilakse stanja taupatije kod pacijenta; ili se upotrebljava u postupku liječenja ili profilakse Alzheimerove bolesti (AD), Pickove bolesti, progresivne supranuklearne palsije (PSP), fronto-temporalne demencije (FTD), fronto-temporalne demencije s parkinsonizmom povezanim na kromosom 17 (FTDP-17), kompleksa disinhibicija-demencija-parkinsonizam-amiotrofija (DDPAC), palido-pronto-nigralne degeneracije (PPND), Guam-ALS-sindroma, palido-nigro-lujzijanske degeneracije (PNLD), ili kortiko-bazalne degeneracije (CBD) kod pacijenta; ili se upotrebljava u postupku dijagnosticiranja ili prognoziranja tau proteinopatije, pri čemu spoj utjelovljuje, konjugiran je na, kelatiran je, ili je udružen na neki drugi način s jednom/jednu ili više oznaka koje se mogu detektirati.
12. Uporaba spoja diaminofenotiazinija, naznačena time, da je za proizvodnju lijeka koji se upotrebljava u postupku liječenja ili profilakse stanja taupatije kod pacijenta, pri čemu je taj spoj odabran od sljedećih:
(A) etil-tioninijev klorid (ETC),
(B) 1,9-dietil-metil-tioninijev klorid (DEMTC),
(C) 1,9-dimetil-etil-tioninijev klorid (DMETC),
(D) 1,9-dietil-etil-tioninijev klorid (DEETC),
(F) mješavina soli etil-tioninijev klorid-zinkov klorid (ETZ),
(G) metil-tioninijev jodid (MTI),
(H) mješavina soli metil-tioninijev jodid-vodikov jodid (MTI.HI),
(I) etil-tioninijev jodid (ETI),
(J) mješavina soli etil-tioninijev jodid-vodikov jodid (ETI.HI),
(L) etil-tioninijev nitrat (ETN).
13. Uporaba prema zahtjevu 12, naznačena time, da je pacijent odabran za liječenje slijedom procjene pomoću kliničke evaluacije i/ili slijedom objektivne evaluacije kognitivne funkcije primjenom neuropatološki validiranih baterija testova.
14. Uporaba spoja diaminofenotiazinija prema zahtjevu 11, naznačena time, da je za liječenje ili profilaksu Alzheimerove bolesti (AD), Pickove bolesti, progresivne supranuklearne palsije (PSP), fronto-temporalne demencije (FTD), fronto-temporalne demencije s parkinsonizmom povezanim na kromosom 17 (FTDP-17), kompleksa disinhibicija-demencija-parkinsonizam-amiotrofija (DDPAC), palido-pronto-nigralne degeneracije (PPND), Guam-ALS-sindroma, palido-nigro-lujzijanske degeneracije (PNLD), ili kortiko-bazalne degeneracije (CBD) kod pacijenta; ili je za proizvodnju dijagnostičkog ili prognostičkog reagensa za primjenu u dijagnozi ili prognozi tau proteinopatije kod pacijenta, pri čemu spoj utjelovljuje, konjugiran je na, kelatiran je, ili je udružen na neki drugi način s jednom/jednu ili više oznaka koje se mogu detektirati.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US78669906P | 2006-03-29 | 2006-03-29 | |
| EP14185157.6A EP2853293B1 (en) | 2006-03-29 | 2007-03-28 | Thioninium compounds and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180204T1 true HRP20180204T1 (hr) | 2018-03-09 |
Family
ID=38163667
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141261TT HRP20141261T1 (en) | 2006-03-29 | 2014-12-29 | Thioninium compounds and their use |
| HRP20180204TT HRP20180204T1 (hr) | 2006-03-29 | 2018-02-02 | Spojevi tioninija i njihova primjena |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20141261TT HRP20141261T1 (en) | 2006-03-29 | 2014-12-29 | Thioninium compounds and their use |
Country Status (14)
| Country | Link |
|---|---|
| EP (2) | EP2853293B1 (hr) |
| JP (1) | JP5184507B2 (hr) |
| CN (2) | CN101460222B (hr) |
| AU (1) | AU2007231127B2 (hr) |
| CA (1) | CA2645919C (hr) |
| DK (2) | DK2853293T3 (hr) |
| ES (2) | ES2525001T3 (hr) |
| HK (2) | HK1121084A1 (hr) |
| HR (2) | HRP20141261T1 (hr) |
| MY (2) | MY172157A (hr) |
| PL (2) | PL2853293T3 (hr) |
| PT (2) | PT2853293T (hr) |
| SI (2) | SI2853293T1 (hr) |
| WO (1) | WO2007110630A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5725605B2 (ja) * | 2007-06-19 | 2015-05-27 | ウイスタ・ラボラトリーズ・リミテッドＷｉｓｔａ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｔｄ． | 軽度認知障害を処置するためのフェノチアジン化合物 |
| WO2010067078A2 (en) * | 2008-12-10 | 2010-06-17 | Wista Laboratories Ltd. | 3,6-disubstituted xanthylium salts as medicaments |
| CN102958525B (zh) | 2010-04-30 | 2017-05-24 | 普罗瑟塔抗病毒股份有限公司 | 抗病毒化合物 |
| HUE031633T2 (en) | 2011-02-11 | 2017-07-28 | Wista Lab Ltd | Phenothiazine diaminium salts and their use |
| CN102690244A (zh) * | 2011-03-22 | 2012-09-26 | 中国科学院上海生命科学研究院 | 调节α-突触核蛋白积聚的物质及其制药用途 |
| WO2012145567A1 (en) | 2011-04-20 | 2012-10-26 | Prosetta Antiviral Inc. | Antiviral compounds |
| GB201317702D0 (en) * | 2013-10-07 | 2013-11-20 | Wista Lab Ltd | Methods of chemical synthesis of diaminophenothiazinium compounds including methylthioninium chloride (MTC) |
| GB201512678D0 (en) | 2015-07-20 | 2015-08-26 | Wista Lab Ltd | Methods of chemical synthesis |
| SG11201900228YA (en) | 2016-07-25 | 2019-02-27 | Wista Lab Ltd | Administration and dosage of diaminophenothiazines |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| GB201621817D0 (en) | 2016-12-21 | 2017-02-01 | Wista Lab Ltd | Methods of chemical synthesis |
| EP3826639A1 (en) | 2018-07-26 | 2021-06-02 | WisTa Laboratories Ltd. | Optimised dosage of diaminophenothiazines in populations |
| US20220049102A1 (en) * | 2019-09-21 | 2022-02-17 | RK Pharma Solutions LLC | Process for the Purification of Methylene Blue |
| GB202010652D0 (en) | 2020-07-10 | 2020-08-26 | Wista Lab Ltd | Anti-tau antibodies |
| WO2023232764A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | Treatment of neurodegenerative disorders utilising methylthioninium (mt)-containing compounds |
| WO2024061971A1 (en) | 2022-09-21 | 2024-03-28 | Wista Laboratories Ltd. | Novel formulations and vehicles |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1996004915A1 (en) * | 1994-08-08 | 1996-02-22 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| JP2000344685A (ja) * | 1999-03-26 | 2000-12-12 | Bf Kenkyusho:Kk | アズールａ類似化合物によるアミロイドが蓄積する疾患の画像診断プローブおよびそれを含む画像診断用組成物 |
| GB0101049D0 (en) * | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) * | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| JP2007512297A (ja) * | 2003-11-28 | 2007-05-17 | フォトファーマイカ リミテッド | 生物活性メチレンブルー誘導体（２）における開発 |
| PT1799662E (pt) | 2004-09-23 | 2013-07-09 | Wista Lab Ltd | Métodos de síntese química e purificação de compostos de diaminofenotiazínio incluindo cloreto de metiltionínio (mtc) |
| CN101084204B (zh) | 2004-09-23 | 2012-12-05 | 卫思道制药有限公司 | 包括亚甲蓝(mtc)在内的二氨基吩噻嗪鎓化合物的化学合成和纯化方法 |
-
2007
- 2007-03-28 CN CN2007800202730A patent/CN101460222B/zh active Active
- 2007-03-28 MY MYPI2014003327A patent/MY172157A/en unknown
- 2007-03-28 SI SI200732008T patent/SI2853293T1/en unknown
- 2007-03-28 DK DK14185157.6T patent/DK2853293T3/en active
- 2007-03-28 EP EP14185157.6A patent/EP2853293B1/en active Active
- 2007-03-28 DK DK07712962.5T patent/DK2001556T3/da active
- 2007-03-28 EP EP07712962.5A patent/EP2001556B1/en active Active
- 2007-03-28 WO PCT/GB2007/001107 patent/WO2007110630A1/en active Application Filing
- 2007-03-28 MY MYPI20083822A patent/MY162640A/en unknown
- 2007-03-28 SI SI200731541T patent/SI2001556T1/sl unknown
- 2007-03-28 ES ES07712962.5T patent/ES2525001T3/es active Active
- 2007-03-28 AU AU2007231127A patent/AU2007231127B2/en active Active
- 2007-03-28 PL PL14185157T patent/PL2853293T3/pl unknown
- 2007-03-28 ES ES14185157.6T patent/ES2659030T3/es active Active
- 2007-03-28 JP JP2009502207A patent/JP5184507B2/ja active Active
- 2007-03-28 PL PL07712962T patent/PL2001556T3/pl unknown
- 2007-03-28 CA CA2645919A patent/CA2645919C/en active Active
- 2007-03-28 PT PT141851576T patent/PT2853293T/pt unknown
- 2007-03-28 CN CN201310514618.5A patent/CN103641794B/zh active Active
- 2007-03-28 PT PT77129625T patent/PT2001556E/pt unknown
-
2009
- 2009-01-14 HK HK09100375.6A patent/HK1121084A1/xx unknown
-
2014
- 2014-12-29 HR HRP20141261TT patent/HRP20141261T1/hr unknown
-
2015
- 2015-09-08 HK HK15108741.8A patent/HK1208000A1/xx unknown
-
2018
- 2018-02-02 HR HRP20180204TT patent/HRP20180204T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DK2001556T3 (da) | 2014-11-10 |
| ES2659030T3 (es) | 2018-03-13 |
| EP2853293A1 (en) | 2015-04-01 |
| EP2853293B1 (en) | 2017-11-22 |
| PT2853293T (pt) | 2018-02-13 |
| CN103641794A (zh) | 2014-03-19 |
| SI2853293T1 (en) | 2018-03-30 |
| DK2853293T3 (en) | 2018-01-22 |
| MY162640A (en) | 2017-06-30 |
| AU2007231127A1 (en) | 2007-10-04 |
| AU2007231127B2 (en) | 2013-03-14 |
| MY172157A (en) | 2019-11-15 |
| CN103641794B (zh) | 2016-09-21 |
| JP2009531405A (ja) | 2009-09-03 |
| CA2645919A1 (en) | 2007-10-04 |
| HRP20141261T1 (en) | 2015-03-13 |
| PT2001556E (pt) | 2014-12-09 |
| PL2001556T3 (pl) | 2015-03-31 |
| PL2853293T3 (pl) | 2018-05-30 |
| EP2001556B1 (en) | 2014-10-01 |
| SI2001556T1 (sl) | 2014-12-31 |
| ES2525001T3 (es) | 2014-12-16 |
| WO2007110630A1 (en) | 2007-10-04 |
| CN101460222A (zh) | 2009-06-17 |
| CA2645919C (en) | 2016-05-31 |
| JP5184507B2 (ja) | 2013-04-17 |
| CN101460222B (zh) | 2013-12-04 |
| EP2001556A1 (en) | 2008-12-17 |
| HK1121084A1 (en) | 2009-04-17 |
| HK1208000A1 (en) | 2016-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180204T1 (hr) | Spojevi tioninija i njihova primjena | |
| ES2727815T3 (es) | Tratamiento del TEPT y de trastornos del control de impulsos | |
| ES2546819T3 (es) | Uso terapéutico de las diaminofenotiazinas | |
| Findling et al. | Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder | |
| Strassnig et al. | Tardive dyskinesia: motor system impairments, cognition and everyday functioning | |
| KR102475825B1 (ko) | 디아미노페노티아진 (diaminophenothiazines)의 투여 및 투여량 (dosage) | |
| CN109071528A (zh) | 用于诊断和治疗的双环化合物 | |
| ES2847929T3 (es) | Tratamiento de la demencia | |
| NO20171934A1 (en) | Compositions and methods of treating a neurodegenerative disease | |
| KR101750119B1 (ko) | 의약으로서 3,6-이중치환된 크산틸륨 염 | |
| US20170042864A1 (en) | Methods of treating hepatic encephalopathy | |
| JP2009531405A5 (hr) | ||
| AU2010271070A1 (en) | Methods of treating hepatic encephalopathy | |
| KR20160110395A (ko) | 헌팅턴병 진행을 지연시키기 위한 라퀴니모드의 용도 | |
| CN104447770A (zh) | 阿塞那平化合物 | |
| CA3189243A1 (en) | Compositions and methods for improving neurological diseases and disorders | |
| BR112019011486B1 (pt) | Método para síntese química de um ácido tiossulfônico através de uma etapa de acoplamento oxidativo mediado por periodato de um ácido tiossulfônico com uma anilina | |
| US8389535B2 (en) | L-methylfolate treatment for psychiatric or neurologic disorders | |
| CA2883851A1 (en) | Methods of improving long-term survival and reducing hospitalization readmission rates for subjects suffering from hepatic encephalopathy | |
| US20240122928A1 (en) | Methods For Treating Agitation In Subjects With Mild Cognitive Impairment Or Major Neurocognition Disorder | |
| Allain et al. | Comparative effects of pharmacotherapy on the maintenance of cognitive function | |
| WO2023225021A1 (en) | Compositions and methods for treating patients with amyotrophic lateral sclerosis (als) | |
| WO2024023696A1 (en) | Dosing regimen for a nlrp3 inhibitor | |
| US20180289655A1 (en) | Methods and Compositions for the Intravenous Administration of Fumarates for the Treatment of Neurological Diseases |